Related Experiment Video
Updated: Aug 12, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Nimodipine in refractory epilepsy: a placebo-controlled, add-on study
J G Larkin1, P J McKee, J Blacklaw
1University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland.
Epilepsy Research
|May 1, 1991
Summary
Nimodipine did not effectively reduce seizures in patients with refractory epilepsy. This adjunctive therapy showed no significant benefit over placebo in a double-blind trial, despite promising animal model results.
Area of Science:
- Clinical Neurology
- Pharmacology
- Epileptology
Background:
- Refractory epilepsy presents a significant challenge in clinical practice.
- Nimodipine, a calcium channel blocker, has shown efficacy in animal models of epilepsy.
- The potential of nimodipine as an adjunctive therapy for human epilepsy requires clinical investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of nimodipine as adjunctive therapy in patients with refractory epilepsy.
- To compare seizure frequency and seizure days between nimodipine treatment and placebo.
- To assess the impact of nimodipine on vital signs and antiepileptic drug levels.
Main Methods:
- A balanced, double-blind, placebo-controlled crossover trial was conducted.
- Twenty-two patients with refractory epilepsy received nimodipine (30, 60, or 90 mg tds) or placebo for 12-week periods, separated by 4-week wash-outs.
- Seizure types, seizure days, side-effects, pulse, blood pressure, and drug levels were monitored.
Main Results:
- Nimodipine did not demonstrate a significant reduction in total, partial, or generalized tonic-clonic seizures compared to placebo.
- Median seizure days remained unchanged between nimodipine and placebo treatment periods.
- No significant differences in side-effects, vital signs, or antiepileptic drug levels were observed; circulating nimodipine levels were low.
Conclusions:
- Nimodipine failed to show therapeutic benefit as an adjunctive treatment for refractory epilepsy in this clinical trial.
- The lack of efficacy may be related to low circulating concentrations or enzyme induction by concurrent antiepileptic drugs.
- Further research is needed to explore potential mechanisms or alternative therapeutic strategies for refractory epilepsy.
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...